Thomas M. Roberts, PhD
Office phone: 617-632-3049
Email: firstname.lastname@example.org .edu
Preferred contact method: email
Area of Research
Signaling Mechanisms and Cancer
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Roberts received his PhD in 1976 from Harvard University, where he also completed a postdoctoral fellowship. In 1981, he joined the DFCI faculty. Dr. Roberts has played a seminal role in discovering the conceptual fabric of signaling downstream from tyrosine kinases. His lab and that of Lewis Cantley, working together, pioneered research on PI3 kinase. He has extended his work to stimulate the discovery of clinically useful inhibitors of oncogenic kinases.
ResearchSignaling Mechanisms and Cancer
Through the process of signal transduction, cells communicate what is happening on their surfaces to the regulatory machinery inside. This process is facilitated by a class of enzymes called kinases, which help activate specific genes in the long strands of DNA in a cell's nucleus. An overactive kinase can lead to an overactive gene and, ultimately, to cancer. Our laboratory is researching the role of these catalysts of cell growth and division and has discovered how several work. Our discoveries have become the basis of new drugs that target the actions of specific kinases. This class of drugs, called kinase inhibitors, offers extraordinary hope for the future of cancer care.
Research in the laboratory currently focuses on three areas. One is how particular kinases are involved in cancer. For instance, the kinase termed PI3K blocks the orderly process of cell death, called apoptosis. Thus, inhibiting PI3K should lead to tumor cell death. We are also exploring new ways to measure kinase activity in tumors. Every tumor is unique, with its own pattern of activated kinases. Because there are more than 600 different kinases in a given tumor, it is important to find which ones are activated so that we know which ones to inhibit. Finally, our laboratory is developing murine model systems to study kinases in tumors.
Once kinases have been pinpointed, our laboratory develops the techniques and technology that allow pharmaceutical companies to make new drugs that target them. We supply the company with the reagents necessary to test the effect of drugs on the action of tyrosine kinases. In addition, DFCI scientists have developed the means to make kinases for testing. This collaboration has led to the creation of several new drugs. In particular, the drug Gleevec has been approved by the FDA against chronic myeloid leukemia (CML). More recently we have been working with Novartis on PI3k inhibitors. PI3K inhbitors from Novartis and other companies are now entering Phase 2 trials.
- Gritsman, Kira, MD, PhD
- Cizmecioglu, Onur, PhD
- Dake (Utermark), Tamara, PhD
- Gao, Xueliang, PhD
- Pores Fernando, Arun, PhD
- Schmit, Fabienne, PhD
- Spangle, Jennifer, PhD
- Xie, Shaozhen, PhD
- Zhang, Jing, PhD
- Tong, Haoxuan, Graduate Student